Allovir

$8.11 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Allovir

AlloVir, Inc. is a late clinical-stage cell therapy company. The Company is engaged in developing allogeneic T cell therapies to treat and prevent viral diseases. Its virus-specific T cell (VST) therapy platform enables to generate VSTs designed to restore immunity in patients with T cell deficiencies. The Company’s product pipeline includes Viralym-M (ALVR105), ALVR106, ALVR109, ALVR107 and ALVR108. Its lead product candidate, Viralym-M, is a multi-VST therapy targeting five viruses: BK virus (BKV), cytomegalovirus (CMV) adenovirus (AdV), Epstein-Barr virus (EBV), and human herpesvirus six (HHV-6). The ALVR106 is an allogeneic VST therapy developed to target diseases caused by four respiratory viruses: respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). LVR109 is an allogeneic VST therapy that targets severe acute respiratory syndrome coronavirus two (SARS-CoV-2).

Stock Analysis

last close $8.49
1-mo return -42.4%
3-mo return -65.4%
avg daily vol. 257.12T
52-week high 47
52-week low 8.46
market cap. $677M
forward pe -
annual div. -
roe -43.4%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 40%
baraka

Subscribe now for daily local and international financial news

Subscribe